ライフサイエンスコーパス: hepatocellular carcinoma

1 r patients with unresectable, liver-confined hepatocellular carcinoma.

2 irst-line therapy for patients with advanced hepatocellular carcinoma.

3 development of diseases such as diabetes and hepatocellular carcinoma.

4 o those with chronic liver failure (CLF) and hepatocellular carcinoma.

5 r adjustment for risk factors not related to hepatocellular carcinoma.

6 use of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

7 that could lead to severe complications and hepatocellular carcinoma.

8 ere more likely to have lower MELDs and have hepatocellular carcinoma.

9 onic infections causing hepatic fibrosis and hepatocellular carcinoma.

10 risk of developing fibrosis, cirrhosis, and hepatocellular carcinoma.

11 orld and often causes fibrosis/cirrhosis and hepatocellular carcinoma.

12 HBV disease worse, including higher rates of hepatocellular carcinoma.

13 ction, which may lead to liver cirrhosis and hepatocellular carcinoma.

14 k of developing end-stage liver diseases and hepatocellular carcinoma.

15 s been shown to have relevance in diagnosing hepatocellular carcinoma.

16 ntial of nivolumab for treatment of advanced hepatocellular carcinoma.

17 survival following liver transplantation for hepatocellular carcinoma.

18 hronic inflammation to tumour development in hepatocellular carcinoma.

19 and duration of fatty liver disease-related hepatocellular carcinoma.

20 higher efficacy than etoposide for treating hepatocellular carcinoma.

21 nals were observed in patients with advanced hepatocellular carcinoma.

22 adult chronic liver disease, cirrhosis, and hepatocellular carcinoma.

23 alities, including steatosis, hepatitis, and hepatocellular carcinoma.

24 gn hepatic tumors to progress into malignant hepatocellular carcinoma.

25 ar consequences of miR-122 downregulation in hepatocellular carcinoma.

26 ymphocyte-mediated regression of established hepatocellular carcinoma.

27 ns greatly limited in cancers, especially in hepatocellular carcinoma.

28 gestive of a common pathogenesis of iCCA and hepatocellular carcinoma.

29 on of the tumor-suppressive sirtuin SIRT6 in hepatocellular carcinoma.

30 al hepatic diseases leading to cirrhosis and hepatocellular carcinoma.

31 sion-free survival in European patients with hepatocellular carcinoma.

32 d man with decompensated liver cirrhosis and hepatocellular carcinoma.

33 role of SLC13A5 in the progression of human hepatocellular carcinoma.

34 n a population with abnormally high rates of hepatocellular carcinoma.

35 due to complications of liver cirrhosis and hepatocellular carcinoma.

36 triglycerides in hepatocytes, which leads to hepatocellular carcinoma.

37 genome instability, progeria and early onset hepatocellular carcinoma.

38 s C virus (HCV) is one of the main causes of hepatocellular carcinoma.

39 velopment of cirrhosis, hepatic failure, and hepatocellular carcinoma.

40 and its implications for the development of hepatocellular carcinoma.

41 disease progression, including cirrhosis and hepatocellular carcinoma.

42 recommendation for surveillance of recurrent hepatocellular carcinoma after liver transplantation (LT

43 or in the etiology of fibrosis/cirrhosis and hepatocellular carcinoma, although the mechanisms for th

44 he CR were histologically verified; 80% were hepatocellular carcinoma and 20% were intrahepatic chola

45 ort that the lncRNA MALAT1 is upregulated in hepatocellular carcinoma and acts as a proto-oncogene th

46 ge (AIM, also called CD5L) prevents obesity, hepatocellular carcinoma and acute kidney injury.

47 dult liver transplantation for patients with hepatocellular carcinoma and cirrhotic livers.

48 : A 55 year old gentleman was diagnosed with hepatocellular carcinoma and concomitant chronic hepatit

49 75 year old lady was diagnosed with advanced hepatocellular carcinoma and concomitant chronic hepatit

50 w the tumor suppressor SIRT6 is regulated in hepatocellular carcinoma and establish the mechanism und

51 +) T lymphocytes, which prevent emergence of hepatocellular carcinoma and express a limited repertoir

52 Liver cancer, primarily encompassing hepatocellular carcinoma and intrahepatic cholangiocarci

53 tes inflammation and promotes development of hepatocellular carcinoma and other liver diseases.

54 ers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gad

55 tion is a major cause of liver cirrhosis and hepatocellular carcinoma and the leading indication for

56 HL-60 (Human promyelocytic leukemia), HepG2 (Hepatocellular carcinoma) and MCF 12A (normal epithelial

57 p of 49 months, 6 patients died, 2 developed hepatocellular carcinoma, and 1 had liver failure, all o

58 the nodules were borderline between HCA and hepatocellular carcinoma, and 3% of patients developed h

59 620 patients with PCLD, 18 240 patients with hepatocellular carcinoma, and 98 567 patients with CLF.

60 f gastrointestinal tract cancers, especially hepatocellular carcinoma, and colorectal cancer.

61 haryngeal carcinoma (NPC), breast cancer and hepatocellular carcinoma, and contributes to NPC's resis

62 NASH are at increased risk for cirrhosis and hepatocellular carcinoma, and diagnosis currently requir

63 vere liver diseases, including cirrhosis and hepatocellular carcinoma, and is one of the most importa

64 for progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-related mortality.

65 transplantation are alcoholic liver disease, hepatocellular carcinoma, and viral hepatitis.

66 , therapy has been extended to patients with hepatocellular carcinoma as well.

67 Purpose Following the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol

68 d diagnostic tools have enabled diagnosis of hepatocellular carcinoma based on noninvasive methods wi

69 with both the frequency and average size of hepatocellular carcinomas being elevated in Neil1(-/-) T

70 survival status-for patients diagnosed with hepatocellular carcinoma between Aug 1, 2006, and April

71 hospitals who were prescribed sorafenib for hepatocellular carcinoma between January 2006 and April

72 tion of KLF6 is linked to the progression of hepatocellular carcinoma, but its contribution to liver

73 care for patients with advanced unresectable hepatocellular carcinoma, but the relation between survi

74 pican-3 (GPC3) is a promising new marker for hepatocellular carcinoma, but the reported values for se

75 st-transplantation survival in patients with hepatocellular carcinoma by use of individualised, preop

76 enger RNA and fusion protein (114 kD) in the hepatocellular carcinoma cell line HUH7, as well as in l

77 ria in sesamol-induced effects using a human hepatocellular carcinoma cell line, HepG2 cells.

78 N2A1-FER fusions in human prostate cancer or hepatocellular carcinoma cells in vitro and in mouse xen

79 the cytotoxic action of sorafenib in murine hepatocellular carcinoma cells.

80 We therefore initiated an African hepatocellular carcinoma consortium aiming to describe t

81 loyment status, education status, history of hepatocellular carcinoma, diabetes, heart failure, atria

82 er HBsAg positivity or viremia had recurrent hepatocellular carcinoma diagnosed within a month of det

83 INTERPRETATION: Characteristics of hepatocellular carcinoma differ between Egypt and other

84 hotics listed for liver transplantation with hepatocellular carcinoma, even in geographic areas of re

85 BACKGROUND & AIMS: Fibrolamellar hepatocellular carcinoma (FL-HCC) is a primary liver can

86 the signature genetic event of fibrolamellar hepatocellular carcinoma (FL-HCC), a rare but lethal liv

87 decompensated cirrhosis from 12.2% to 4.5%, hepatocellular carcinoma from 9.1% to 4.0%, liver transp

88 ular carcinoma, and 3% of patients developed hepatocellular carcinoma from HCA.

89 nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma, gallstones, acute pancreatitis

90 Whereas CD8(+) T-cell ablation accelerates hepatocellular carcinoma, genetic or pharmacological int

91 rd Associated with Liver Transplantation for Hepatocellular Carcinoma; HALT-HCC) assessed the associa

92 was associated with a decreased incidence of hepatocellular carcinoma (hazard ratio [HR] compared wit

93 centage of patients with CLF from NASH), and hepatocellular carcinoma (HCC) (decreases in percentages

94 g-term outcomes of patients with early-stage hepatocellular carcinoma (HCC) after radiofrequency abla

95 n used to treat intrahepatic recurrent small hepatocellular carcinoma (HCC) against the diaphragmatic

96 reatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sus

97 ol mouse livers, as well as in matched human hepatocellular carcinoma (HCC) and benign liver tissue t

98 es have identified hepatic tumors with mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (C

99 chemoembolization (ACE) in the treatment of hepatocellular carcinoma (HCC) and compare with a simila

100 s (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments fo

101 ntify differentially methylated enhancers in hepatocellular carcinoma (HCC) and experimentally confir

102 re they are a growing cause of cirrhosis and hepatocellular carcinoma (HCC) and increasingly an indic

103 : Little is known about the absolute risk of hepatocellular carcinoma (HCC) and liver-disease related

104 with cirrhosis increases early detection of hepatocellular carcinoma (HCC) and prolongs survival.

105 ackground of high morbidity and mortality of hepatocellular carcinoma (HCC) and rapid development of

106 Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate

107 of cirrhotic nodules and early diagnosis of hepatocellular carcinoma (HCC) are of vital importance.

108 Here, using hepatocellular carcinoma (HCC) as a cancer model, we hav

109 Patients with hepatocellular carcinoma (HCC) can receive Model for End

110 roliferation and induce cell cycle arrest in hepatocellular carcinoma (HCC) cell lines.

111 ted that the MCU complex was dysregulated in hepatocellular carcinoma (HCC) cells and significantly c

112 e et al ( 1 ) describe a unique mechanism of hepatocellular carcinoma (HCC) cells for surviving ische

113 Hepatocellular carcinoma (HCC) cells often invade the po

114 Purpose To characterize hepatocellular carcinoma (HCC) cells surviving ischemia

115 Application of DEIsoM to an hepatocellular carcinoma (HCC) dataset identifies biolog

116 DCEMRI) and contrast-enhanced CT (DCECT) for hepatocellular carcinoma (HCC) detection.

117 ipid homeostasis was also shown to attenuate hepatocellular carcinoma (HCC) development, thus implica

118 f treatment in patients developing recurrent hepatocellular carcinoma (HCC) following liver transplan

119 Surveillance by ultrasonography for hepatocellular carcinoma (HCC) for individuals with cirr

120 em (LI-RADS) version 2014 in differentiating hepatocellular carcinoma (HCC) from non-HCC malignancy i

121 inical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due

122 on between AAV2 integration events and human hepatocellular carcinoma (HCC) has generated controversy

123 ed method for the diagnosis and prognosis of hepatocellular carcinoma (HCC) has not yet been develope

124 Hepatocellular carcinoma (HCC) has the second lowest 5-y

125 g CD4(+) and CD8(+) T cells in patients with hepatocellular carcinoma (HCC) have been found to be fun

126 ve the efficacy of radiation therapy against hepatocellular carcinoma (HCC) have been investigated.

127 ROUND & AIMS: The incidence and mortality of hepatocellular carcinoma (HCC) have been reported to be

128 nd increased expression of FAM83H and MYC in hepatocellular carcinoma (HCC) have been reported.

129 eping beauty transposon/transposase leads to hepatocellular carcinoma (HCC) in mice that corresponds

130 Statin use also decreases the risk of hepatocellular carcinoma (HCC) in patients with chronic

131 ) are both used for noninvasive diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosi

132 Concern has arisen about the development of hepatocellular carcinoma (HCC) in patients with hepatiti

133 Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepa

134 ts with Hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) involves components of vi

135 Hepatocellular carcinoma (HCC) is a common cancer that f

136 Hepatocellular carcinoma (HCC) is a major health threat

137 As prognosis of patients with metastatic hepatocellular carcinoma (HCC) is mainly determined by i

138 Hepatocellular carcinoma (HCC) is more prevalent in men

139 most frequent chromosomal structural loss in hepatocellular carcinoma (HCC) is of the short arm of ch

140 The aerobic glycolytic phenotype of hepatocellular carcinoma (HCC) is often correlated with

141 Hepatocellular carcinoma (HCC) is one of the most common

142 Hepatocellular carcinoma (HCC) is one of the most deadly

143 Hepatocellular carcinoma (HCC) is one of the most freque

144 Hepatocellular carcinoma (HCC) is one of the most preval

145 ntial diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is sometimes difficult.

146 Hepatocellular carcinoma (HCC) is the leading cause of d

147 Hepatocellular carcinoma (HCC) is the only cancer for wh

148 Hepatocellular carcinoma (HCC) is the second leading cau

149 Hepatocellular carcinoma (HCC) is the second leading cau

150 Hepatocellular carcinoma (HCC) is the second-leading cau

151 Hepatocellular carcinoma (HCC) is the third leading caus

152 Hepatocellular carcinoma (HCC) is the third leading form

153 Hepatocellular carcinoma (HCC) is the third most deadly

154 (HCV) infection leads to such a high rate of hepatocellular carcinoma (HCC) is unknown.

155 estigated the possibility that patients with hepatocellular carcinoma (HCC) listed for liver transpla

156 survival (ITT-OS) of cirrhotic patients with hepatocellular carcinoma (HCC) listed for living donor l

157 tumor activity in in vitro and in vivo human hepatocellular carcinoma (HCC) model.

158 Hepatocellular carcinoma (HCC) occurs more frequently an

159 CGA RNA-seq data acquired from patients with hepatocellular carcinoma (HCC) on tumors samples and the

160 all-oral DAA regimen among HCV patients with hepatocellular carcinoma (HCC) or decompensated cirrhosi

161 nitially resectable and transplantable (R&T) hepatocellular carcinoma (HCC) patients, to try to obvia

162 eceptor is responsible for poor prognosis of hepatocellular carcinoma (HCC) patients.

163 ta) signaling pathway is a common feature of hepatocellular carcinoma (HCC) progression.

164 everal factors are associated with increased hepatocellular carcinoma (HCC) recurrence after liver tr

165 plant bridging locoregional therapy (LRT) on hepatocellular carcinoma (HCC) recurrence and survival a

166 lvage liver transplantation (SLT) in case of hepatocellular carcinoma (HCC) recurrence is an alternat

167 Hepatocellular carcinoma (HCC) represents the fifth-most

168 CKGROUND DATA: Salvage transplantation after hepatocellular carcinoma (HCC) resection is limited to p

169 t wait time before liver transplant (LT) for hepatocellular carcinoma (HCC) results in the inclusion

170 Individualized assessment of hepatocellular carcinoma (HCC) risk in chronic liver dis

171 correlation between HDM2 and HBx in clinical hepatocellular carcinoma (HCC) samples.

172 lance benefits when determining the value of hepatocellular carcinoma (HCC) screening programs.

173 y expressed in approximately 60-70% of human hepatocellular carcinoma (HCC) specimens.

174 patients with cirrhosis are nonadherent with hepatocellular carcinoma (HCC) surveillance recommendati

175 ), a p53 mutant frequently detected in human hepatocellular carcinoma (HCC) that is highly related to

176 er Genome Atlas, Oncomine, PrognoScan, and a hepatocellular carcinoma (HCC) tissue microarray.

177 mes, FUT1, FUT2, B3GALT5 and ST3GAL2, in 135 hepatocellular carcinoma (HCC) tissues by qRT-PCR.

178 ed transcriptome data from 242 patients with hepatocellular carcinoma (HCC) to search for gene signat

179 Hepatocellular carcinoma (HCC) typically results from a

180 A) in the treatment of unresectable solitary hepatocellular carcinoma (HCC) up to 3 cm.

181 Here, we interrogated these compartments in hepatocellular carcinoma (HCC) using high-dimensional pr

182 this study were to quantify heterogeneity in hepatocellular carcinoma (HCC) using multiparametric mag

183 (RFA) for patients with inoperable localized hepatocellular carcinoma (HCC) who are eligible for both

184 in the treatment of patients with inoperable hepatocellular carcinoma (HCC) who are ineligible for th

185 Patients with hepatocellular carcinoma (HCC) who are listed for liver

186 gan Sharing (UNOS) database in patients with hepatocellular carcinoma (HCC) who meet Milan criteria b

187 e markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver

188 are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses

189 al outcomes for patients with advanced-stage hepatocellular carcinoma (HCC) with portal vein thrombos

190 As proof of principle, we examined hepatocellular carcinoma (HCC), a cancer that is derived

191 growth factor receptor FGFR4 by FGF19 drives hepatocellular carcinoma (HCC), a disease with few, if a

192 Here we provide evidence that cells from hepatocellular carcinoma (HCC), a highly metastatic canc

193 Hepatocellular carcinoma (HCC), a primary malignancy of

194 rogression and reduce the risk of cirrhosis, hepatocellular carcinoma (HCC), and CHB-associated morta

195 ses from chronic HCV to fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and death.

196 velopment of end-stage liver disease (ESLD), hepatocellular carcinoma (HCC), and liver-related death

197 sAg), prevalent hepatic decompensation (HD), hepatocellular carcinoma (HCC), and those treated for HC

198 nriched and potentially clonally expanded in hepatocellular carcinoma (HCC), and we identified signat

199 kemia (T-ALL) and progressive development of hepatocellular carcinoma (HCC), both lethal diseases.

200 from three of the most common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC)

201 ease (NAFLD) represents an emerging cause of hepatocellular carcinoma (HCC), especially in non-cirrho

202 Primary liver cancer comprises hepatocellular carcinoma (HCC), intrahepatic cholangioca

203 nt role in the pathogenesis of cirrhosis and hepatocellular carcinoma (HCC), most cases of which are

204 ed by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often associated with ch

205 pha-fetoprotein (AFP), a serum biomarker for hepatocellular carcinoma (HCC), the assay has high purif

206 Angiogenesis plays an important role in hepatocellular carcinoma (HCC), the inhibition of which

207 In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibito

208 ts with metastatic adenocarcinoma and 5 with hepatocellular carcinoma (HCC), were examined.

209 e recognized as independent risk factors for hepatocellular carcinoma (HCC).

210 ld and it is a common cause of cirrhosis and hepatocellular carcinoma (HCC).

211 nomogram derived from BCLC for patients with hepatocellular carcinoma (HCC).

212 actful copy number gains in E2F1 and E2F3 in hepatocellular carcinoma (HCC).

213 ion and functional analysis of patients with hepatocellular carcinoma (HCC).

214 non-coding RNAs (lncRNAs) is dysregulated in hepatocellular carcinoma (HCC).

215 ation (TAE), a purely ischemic treatment for hepatocellular carcinoma (HCC).

216 rhosis and predisposes to the development of hepatocellular carcinoma (HCC).

217 ch on Cancer) Group 1 carcinogen that causes hepatocellular carcinoma (HCC).

218 ncogenic event in diverse cancers, including hepatocellular carcinoma (HCC).

219 its impact on OS in patients with metastatic hepatocellular carcinoma (HCC).

220 itor approved for several cancers, including hepatocellular carcinoma (HCC).

221 currence After Liver transplant" (MORAL) for hepatocellular carcinoma (HCC).

222 active therapy and outcomes of patients with hepatocellular carcinoma (HCC).

223 sible for hepatitis, fatty liver disease and hepatocellular carcinoma (HCC).

224 tion and functions during the progression of hepatocellular carcinoma (HCC).

225 that displays hepatosteatosis progressing to hepatocellular carcinoma (HCC).

226 imaging examinations in patients at risk for hepatocellular carcinoma (HCC).

227 associated protein (YAP) activation promotes hepatocellular carcinoma (HCC).

228 ved drug for treating patients with advanced hepatocellular carcinoma (HCC).

229 Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC).

230 RISC, has been implicated as an oncogene in hepatocellular carcinoma (HCC).

231 us feature associated with cancer, including hepatocellular carcinoma (HCC).

232 tage Liver Disease (MELD) at WL was >/=15 or hepatocellular carcinoma (HCC).

233 erapeutic approved for treatment of advanced hepatocellular carcinoma (HCC).

234 s B and C viruses are risk factors for human hepatocellular carcinoma (HCC).

235 network to maintain liver size and suppress hepatocellular carcinoma (HCC).

236 hronic liver diseases (CLDs) predisposing to hepatocellular carcinoma (HCC).

237 ARID1A in the development and progression of hepatocellular carcinoma (HCC).

238 g SLK outcomes in patients undergoing LT for hepatocellular carcinoma (HCC).

239 Hepatocellular carcinomas (HCC) contain a subpopulation

240 More than 80% of hepatocellular carcinomas (HCCs) develop in fibrotic or

241 Hepatocellular carcinomas (HCCs) exhibit a diversity of

242 Human hepatocellular carcinomas (HCCs) expressing the biliary/

243 Global distribution of hepatocellular carcinomas (HCCs) is dominated by its inc

244 lar features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether th

245 Human hepatocellular carcinomas (HCCs), which arise on a backg

246 n the cell surface of an HCV core-expressing hepatocellular carcinoma (HepG2) cell line or immortaliz

247 policy strategies to decrease the burden of hepatocellular carcinoma in Africa.

248 n, management, and outcomes of patients with hepatocellular carcinoma in Africa.

249 Hepatitis C virus was the leading cause of hepatocellular carcinoma in Egypt (1054 [84%] of 1251 pa

250 elp explain the extraordinarily high rate of hepatocellular carcinoma in Mongolia.

251 ic disturbances and in the increased risk of hepatocellular carcinoma in patients with AAT deficiency

252 oderate alcohol use may increase the risk of hepatocellular carcinoma in patients with advanced fibro

253 atures were associated with a higher risk of hepatocellular carcinoma in patients with SVRs, but not

254 patients received treatment specifically for hepatocellular carcinoma in the other African countries

255 Hepatocellular carcinoma is a leading cause of cancer-re

256 Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminate

257 3A5 affects the metabolism and malignancy of hepatocellular carcinoma is unknown.

258 e (NAFLD), a common prelude to cirrhosis and hepatocellular carcinoma, is the most common chronic liv

259 enzymes in 10 matched pericarcinomatous and hepatocellular carcinoma liver samples.

260 oreover, levels of M30 and M65 predicted non-hepatocellular carcinoma liver-related mortality in pati

261 tes, encephalopathy, and variceal bleeding), hepatocellular carcinoma, liver transplantation, and liv

262 hotics listed for liver transplantation with hepatocellular carcinoma MELD exception points.

263 in vitro and in a patient-derived orthotopic hepatocellular carcinoma model in mice.

264 ch lncRNA MALAT1 acts as a proto-oncogene in hepatocellular carcinoma, modulating oncogenic alternati

265 rticles in combination with RF ablation in a hepatocellular carcinoma mouse model.

266 on-coding RNA (lincRNA) profiles compared to hepatocellular carcinoma (n = 263) and cholangiocarcinom

267 TZ-HFD) induced nonalcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC) murine model and com

268 it would have been expected that the rate of hepatocellular carcinoma occurrence is markedly decrease

269 ad treatment interrupted at 17 months due to hepatocellular carcinoma, one patient had dose interrupt

270 ith the AAV-BR1-CAG-NEMO vector developed no hepatocellular carcinoma or other major adverse effects

271 diseases, a grey area exists with regard to hepatocellular carcinoma or other tumour types in childr

272 rus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or missing HCV RNA or FIB-4 sc

273 Consistently, analysis of 160 hepatocellular carcinoma patient specimens indicated tha

274 n serum was higher (>8.5 fold, P < 0.001) in hepatocellular carcinoma patients compared to healthy an

275 In some hepatocellular carcinoma patients, ARID1A was highly exp

276 e surveillance imaging schedules for post-LT hepatocellular carcinoma patients.

277 tumor, and adjacent normal tissues from six hepatocellular carcinoma patients.

278 ss of liver transplantation in patients with hepatocellular carcinoma poorly estimate post-transplant

279 to participate in the consortium to develop hepatocellular carcinoma research databases and biospeci

280 We also analyzed hepatocellular carcinoma samples and show these solid tu

281 s, mental confusion, hepatic encephalopathy, hepatocellular carcinoma, severe anemia, untreated hypot

282 For patients with advanced hepatocellular carcinoma, sorafenib is the only approved

283 sed tumor ablation is successful in treating hepatocellular carcinomas, the necessity for multiple tr

284 that AMC may be a novel promising agent for hepatocellular carcinoma treatment.

285 urvival of patients treated for unresectable hepatocellular carcinoma (uHCC) with (90)Y transarterial

286 sAg-positive patients with liver fibrosis or hepatocellular carcinoma was 5.24 (95% CI 2.74-10.01; p<

287 No evidence of hepatocellular carcinoma was detected.

288 decompensated liver disease, or a history of hepatocellular carcinoma were excluded.

289 X-E12 (colorectal adenocarcinoma) and HepG2 (hepatocellular carcinoma), were used to investigate the

290 LL3 and ARID1B, which are mutated in >50% of hepatocellular carcinomas, were also mutated in liver me

291 over, we show that USP21 is overexpressed in hepatocellular carcinoma, where it promotes BRCA2 stabil

292 he dichotomous nature of Gal-9 is evident in hepatocellular carcinoma, where loss of expression in he

293 rment of liver functions and, in some cases, hepatocellular carcinoma, whereas decline of AAT levels

294 Finally, by comparing murine hepatocellular carcinomas, which developed in p53 wild-t

295 of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibito

296 We used data from 420 patients with hepatocellular carcinoma who underwent liver transplanta

297 ckpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral h

298 ears) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or

299 is or reflux is a concern, in the setting of hepatocellular carcinoma with portal vein invasion, and

300 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single ag